Peritoneal Dialysis Market - Global Forecast to 2029
商品番号 : SMB-66826
| 出版社 | MarketsandMarkets |
| 出版年月 | 2024年10月 |
| ページ数 | 253 |
| 図表数 | 307 |
| 価格タイプ | シングルユーザライセンス |
| 価格 | USD 4,950 |
| 種別 | 英文調査報告書 |
Report Overview
The peritoneal dialysis market is projected to reach USD 12.70 Billion by 2029 from USD 9.58 Billion in 2024 at a CAGR of 5.8% during the forecast period.
腹膜透析市場は、予測期間中に5.8%のCAGRで2024年の95.8億米ドルから2029年までに127.0億米ドルに達すると予測されています。
Favorable healthcare policies in developed markets have highly increased access to peritoneal dialysis since many now offer reimbursements for home-based dialysis treatments. In most cases, the United States, Canada, and several others in Europe have come up with policies that acknowledge the cost-effectiveness and better benefits for patients through peritoneal dialysis over in-center hemodialysis. Such policies reduce the barriers associated with the cost of treatment by establishing reimbursement coverage for a significant portion of the PD-associated treatment costs. This could make PD a much more affordable and accessible form of therapy for patients, and reimbursement programs promote the practice of healthcare providers to recommend PD due to its flexibility and practicality, also for those preferring home management of treatment. For instance, in the United States, Medicare’s ESRD program encourages wider adoption by providing reimbursements for home dialysis. Likewise, other developed markets also are following and encouraging home dialysis since it reduces hospital admissions, improves patient outcomes, and reduces burdens on the healthcare facilities. The financial support that comes with PD has become a reason for the aged and bedridden patients who have been able to live better as a result of reduced immobilization and enhanced personal care.
“The peritoneal solution bags segment is accounted for the largest share of peritoneal dialysis market.”
Peritoneal dialysis solution bags are less expensive than machines because they are not reliant upon pricey technology and maintenance. Because of this, these bags are very inexpensive for patients and healthcare systems, whose production and distribution costs make it possible to sell these bags at prices within everyone’s reach, especially in countries that have tightly constrained health care budgets. Solution bags also reduce the requirement for costly equipment and training of the staff, thereby reducing the overall cost of treatment. This adds to the attractiveness of solution bags as a treatment option for a larger number of patients in resource-poor settings for access to necessary dialysis.
“Continuous Ambulatory Peritoneal Dialysis (CAPD) segment holds the largest market share of peritoneal dialysis market.”
The increased coverage of CAPD supplies, especially the solution bags, has stimulated its adoption, especially in developing countries. CAPD, being any form of dialysis treatment, requires only basic supplies, like solution bags, and hence is much simpler to distribute and implement in areas with very poor healthcare resources than expensive machinery. Therefore, it is more cost-effective and accessible to patients in low-resource settings as a practically offered form of dialysis. Ease of use and minimization of the use of hospital facilities further increase the adoption rate of CAPD, thereby increasing access to dialysis care in underprivileged areas globally.
“End-stage renal disease segment holds the largest market share in the global peritoneal dialysis market and expected to grow at the highest CAGR during the forecast period”
Most healthcare systems promote home dialysis options to decrease the prevalence of hospital visits attributed to end-stage renal disease (ESRD), which subsequently saves the overall cost of healthcare. Health care providers would benefit from home peritoneal dialysis by reducing the need for in-center dialysis, thus saving hospital facility capacities and minimizing the problems it poses both to facilities and personnel. Home dialysis will also improve patients’ lives as they assume control over their treatment. An added advantage of home-based PD is that it is very economical since it saves transportation costs, it minimizes the susceptibility to infection, and encourages continuity of care, which makes it an attractive modality for health care systems.
“Home care setttings segment accounted for the largest market share in the global peritoneal dialysis market and expected to grow at the highest CAGR during the forecast period.”
Portable and user-friendly dialysis equipment have further improved the safety and ease of treatment in the home setting for patients. Modern peritoneal dialysis machines are well designed with intuitive interfaces, automation, and compact size, making them devices that patients can use with relative ease, without relying so much on medical knowledge. Thus, independent and comfortable home-based dialysis has reduced a patient’s dependence on healthcare professionals. Safety measures have upgraded with live monitoring and automatic alarms that enhanced outcomes best dealt with early before dangers occur. In those innovations, patient confidence in handling their care improved, while the treatment compliance was generally enhanced.
“North America to witness the substantial growth rate during the forecast period.”
The peritoneal dialysis market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa and GCC Countries based on the region type. In 2023, the Asia Pacific region is projected to exhibit the highest CAGR during the forecast period. However, North America accounts for the largest market share of the peritoneal dialysis market in 2023. North America is the largest regional market for global peritoneal dialysis, and this is partly because healthcare providers in this region have been trained specifically to manage this treatment. This places them in a better position to ensure that patients requiring the treatment receive a holistic education on how to carry out procedures safely and effectively at home. Moreover, these professionals provide timely interventions through effective monitoring, thus making the outcomes better as well as complications as low as possible. Specialized training programs and ongoing professional development in the region further underpin quality care. Such professionalism among healthcare professionals has indeed contributed to success in the introduction and spread of peritoneal dialysis in North America.
A breakdown of the primary participants (supply-side) for the peritoneal dialysis market referred to for this report is provided below:
- By Company Type: Tier 1–45%, Tier 2–30%, and Tier 3–25%
- By Designation: C-level–35%, Director Level–25%, and Others–40%
- By Region: North America–40%, Europe–20%, Asia Pacific–25%, Latin America- 10%, and Middle East and Africa– 3% and GCC Countries– 2%
Prominent players in this market include Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US), Utah Medical Products, Inc. (US), Terumo Corporation (Japan), Diaverum AB (Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd (India), JMS Co., Ltd. (Japan), AMECATH (Egypt), Polymedicure (India), Huaren Pharmaceutical (China), AWAK Technologies (Singapore), Innovative Renal Care (US), Romsons (India), SSEM Mthembu Medical (Pty) Ltd (South Africa), Renax Biomedical Technology Co., Ltd (China), and Advin Health Care (India).
Research Coverage:
The market study covers the peritoneal dialysis market across various segments. It aims at estimating the market size and the growth potential of this market across different segments by offering, modality, disease indication, end user and region. The study also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, key observations related to their product and business offerings, recent developments, and key market strategies.
Reasons to Buy the Report
This report will enrich established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share of the market. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their positions in the market.
This report provides insights on:
Analysis of Market Dynamics: Drivers (rising prevalence of chronic kidney diseases, growing prevalence of diabetes and hypertension, and technological advancements and increased investment in R&D) restraints (underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs)) opportunities (increasing growth opportunities in emerging economies, and surge in demand for home dialysis treatment), and challenges (growing incidence of treated kidney failure, and shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs))
- Services/Innovations: Detailed insights on upcoming technologies, research & development activities, and new product launches in the peritoneal dialysis market.
- Market Development: Comprehensive information on the lucrative emerging markets, components, demographics, end-user, and region.
- Market Diversification: Exhaustive information about the product portfolios, growing geographies, recent developments, and investments in the peritoneal dialysis market.
- Competitive Assessment: In-depth assessment of market shares, growth strategies, product offerings, and capabilities of the leading players in the peritoneal dialysis market like Baxter International Inc. (US), Fresenius Medical Care AG (Germany), Medtronic plc (Ireland), Davita Inc. (US), Becton, Dickinson and Company (US).
Table of Contents
1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.2.1 INCLUSIONS & EXCLUSIONS 25
1.3 STUDY SCOPE 26
1.3.1 MARKETS COVERED 26
1.3.2 YEARS CONSIDERED 27
1.4 CURRENCY CONSIDERED 27
1.5 STAKEHOLDERS 28
1.6 IMPACT OF AI/GEN AI 28
2 RESEARCH METHODOLOGY 29
2.1 RESEARCH DATA 29
2.1.1 SECONDARY DATA 30
2.1.2 PRIMARY DATA 32
2.2 MARKET SIZE ESTIMATION 34
2.2.1 REVENUE MAPPING-BASED MARKET ESTIMATION 34
2.2.2 COMPANY PRESENTATIONS AND PRIMARY INTERVIEWS 36
2.2.3 USAGE-BASED MARKET ESTIMATION 37
2.2.4 PRIMARY RESEARCH VALIDATION 39
2.3 GROWTH FORECAST ESTIMATION 39
2.4 MARKET BREAKDOWN & DATA TRIANGULATION 41
2.5 STUDY ASSUMPTIONS 42
2.6 RISK ASSESSMENT 42
2.7 RESEARCH LIMITATIONS 42
3 EXECUTIVE SUMMARY 43
4 PREMIUM INSIGHTS 48
4.1 PERITONEAL DIALYSIS MARKET OVERVIEW 48
4.2 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET, BY OFFERING (2023) 49
4.3 PERITONEAL DIALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
4.4 REGIONAL MIX: PERITONEAL DIALYSIS MARKET (2024−2029) 51
4.5 PERITONEAL DIALYSIS MARKET: DEVELOPED VS. DEVELOPING ECONOMIES 51
5 MARKET OVERVIEW 52
5.1 INTRODUCTION 52
5.2 MARKET DYNAMICS 52
5.2.1 DRIVERS 53
5.2.1.1 Rising prevalence of chronic kidney diseases 53
5.2.1.2 Growing prevalence of diabetes and hypertension 54
5.2.1.3 Technological advancements and increased investment in R&D 55
5.2.2 RESTRAINTS 56
5.2.2.1 Underutilization of peritoneal dialysis in low-income and lower-middle-income countries (LLMICs) 56
5.2.3 OPPORTUNITIES 57
5.2.3.1 Increasing growth opportunities in emerging economies 57
5.2.3.2 Surge in demand for home dialysis treatment 58
5.2.4 CHALLENGES 58
5.2.4.1 Shortage of skilled nephrologists in low-income and lower-middle-income countries (LLMICs) 58
5.2.4.2 High risk of peritonitis as a barrier to peritoneal dialysis adoption 59
5.3 INDUSTRY TRENDS 59
5.3.1 INCREASED ADOPTION OF HOME-BASED TREATMENTS 59
5.3.2 RISING INCIDENCE OF CHRONIC KIDNEY DISEASE (CKD) 60
5.4 TECHNOLOGY ANALYSIS 60
5.4.1 KEY TECHNOLOGIES 60
5.4.1.1 Automated peritoneal dialysis (APD) machines 60
5.4.2 COMPLEMENTARY TECHNOLOGIES 61
5.4.2.1 Remote monitoring systems 61
5.4.3 ADJACENT TECHNOLOGIES 61
5.4.3.1 Wearable technology 61
5.5 SUPPLY CHAIN ANALYSIS 61
5.6 VALUE CHAIN ANALYSIS 63
5.7 TRADE ANALYSIS 63
5.7.1 TRADE ANALYSIS FOR PERITONEAL DIALYSIS MACHINES, SOLUTION BAGS, CATHETERS, AND TRANSFER SETS (HS CODE 9018) 63
5.8 PORTER’S FIVE FORCES ANALYSIS 65
5.8.1 THREAT OF NEW ENTRANTS 66
5.8.2 THREAT OF SUBSTITUTES 66
5.8.3 BARGAINING POWER OF SUPPLIERS 66
5.8.4 BARGAINING POWER OF BUYERS 66
5.8.5 INTENSITY OF COMPETITIVE RIVALRY 66
5.9 REGULATORY ANALYSIS 67
5.9.1 REGULATORY LANDSCAPE 67
5.9.1.1 North America 67
5.9.1.1.1 US 67
5.9.1.1.2 Canada 67
5.9.1.2 Europe 67
5.9.1.3 Asia Pacific 68
5.9.1.3.1 India 68
5.9.1.3.2 China 68
5.9.1.3.3 Japan 68
5.9.1.3.4 South Korea 68
5.9.1.4 Latin America 69
5.9.1.4.1 Brazil 69
5.9.1.4.2 Mexico 69
5.9.1.5 Middle East 69
5.9.1.6 Africa 70
5.9.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 70
5.10 PATENT ANALYSIS 72
5.10.1 PATENT PUBLICATION TRENDS FOR PERITONEAL DIALYSIS MARKET 72
5.10.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS 73
5.11 PRICING ANALYSIS 74
5.11.1 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER (2023) 74
5.12 KEY CONFERENCES & EVENTS, 2024–2025 75
5.13 KEY STAKEHOLDERS & BUYING CRITERIA 76
5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 76
5.13.2 KEY BUYING CRITERIA 77
5.14 ECOSYSTEM ANALYSIS 78
5.15 ADJACENT MARKET ANALYSIS 79
5.15.1 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET 79
5.15.2 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET 80
5.16 CASE STUDY ANALYSIS 81
5.17 IMPACT OF GENERATIVE AI ON PERITONEAL DIALYSIS MARKET 82
5.18 UNMET NEEDS AND END-USER EXPECTATIONS 83
5.19 TRENDS/DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES 84
5.20 INVESTMENT & FUNDING SCENARIO 84
5.21 PROCEDURE DATA ANALYSIS 85
5.21.1 PREVALENCE DATA FOR TREATED KIDNEY FAILURE 86
6 PERITONEAL DIALYSIS MARKET, BY OFFERING 90
6.1 INTRODUCTION 91
6.2 PERITONEAL DIALYSIS PRODUCTS 91
6.2.1 PERITONEAL DIALYSIS SOLUTION BAGS 93
6.2.1.1 High demand for solutions to boost segmental growth 93
6.2.2 PERITONEAL DIALYSIS MACHINES 95
6.2.2.1 Rising prevalence of chronic diseases in emerging economies to boost adoption 95
6.2.3 PERITONEAL DIALYSIS CATHETERS 97
6.2.3.1 Favorable reimbursement policies to support market growth 97
6.2.4 PERITONEAL DIALYSIS TRANSFER SETS 98
6.2.4.1 Product recalls to limit market growth 98
6.2.5 OTHER PERITONEAL DIALYSIS PRODUCTS 99
6.3 PERITONEAL DIALYSIS SERVICES 100
6.3.1 BETTER PRIVACY AND INCREASED COMFORT OF AT-HOME DIALYSIS TREATMENT TO DRIVE MARKET 100
7 PERITONEAL DIALYSIS MARKET, BY MODALITY 102
7.1 INTRODUCTION 103
7.2 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) 103
7.2.1 SUPERIOR CLEARANCE OF HIGH-MOLECULAR-WEIGHT SUBSTANCES TO DRIVE MARKET 103
7.3 AUTOMATED PERITONEAL DIALYSIS (APD) 104
7.3.1 RISK OF RAPID DECLINE IN RESIDUAL RENAL FUNCTIONS TO LIMIT ADOPTION 104
8 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION 106
8.1 INTRODUCTION 107
8.2 END-STAGE RENAL DISEASE 107
8.2.1 GROWING GERIATRIC POPULATION AND INCREASING PREVALENCE OF DIABETES TO DRIVE MARKET 107
8.3 ACUTE KIDNEY INJURY 108
8.3.1 INCREASING HOSPITALIZATIONS TO PROPEL MARKET GROWTH 108
8.4 OTHER DISEASES 110
9 PERITONEAL DIALYSIS MARKET, BY END USER 111
9.1 INTRODUCTION 112
9.2 HOME CARE SETTINGS 112
9.2.1 LOWER COST AND SHORTER HOSPITAL STAYS TO AID MARKET GROWTH 112
9.3 HOSPITALS & INDEPENDENT DIALYSIS CENTERS 113
9.3.1 IMPROVED FACILITIES AND INCREASED GOVERNMENT SUPPORT TO DRIVE MARKET 113
9.4 OTHER END USERS 115
10 PERITONEAL DIALYSIS MARKET, BY REGION 117
10.1 INTRODUCTION 118
10.1.1 PERITONEAL DIALYSIS PREVALENCE DATA 118
10.1.2 PERITONEAL DIALYSIS PROCEDURE DATA 119
10.2 NORTH AMERICA 121
10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 121
10.2.2 US 125
10.2.2.1 US to account for largest market share during study period 125
10.2.3 CANADA 128
10.2.3.1 Shortage of dialysis facilities and increased treatment cost
to limit market 128
10.3 EUROPE 130
10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 131
10.3.2 GERMANY 133
10.3.2.1 Rising number of end-stage renal disease (ESRD) patients to boost market growth 133
10.3.3 UK 136
10.3.3.1 Increased number of new dialysis centers and technological advancements to support market growth 136
10.3.4 FRANCE 138
10.3.4.1 Low cost of peritoneal dialysis and consistent reimbursement policies to drive market growth 138
10.3.5 ITALY 141
10.3.5.1 Increasing research activities and growing patient population with acute renal failure to augment market growth 141
10.3.6 SPAIN 143
10.3.6.1 Favorable reimbursement scenario to boost market growth 143
10.3.7 REST OF EUROPE 146
10.4 ASIA PACIFIC 148
10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 148
10.4.2 JAPAN 153
10.4.2.1 High prevalence of end-stage renal disease (ESRD) and large geriatric population to support market growth 153
10.4.3 CHINA 157
10.4.3.1 Increasing prevalence of diabetes and hypertension to drive market 157
10.4.4 INDIA 159
10.4.4.1 Favorable government initiatives and high prevalence of kidney disease to fuel market growth 159
10.4.5 AUSTRALIA 162
10.4.5.1 Increasing government initiatives about renal care to support market growth 162
10.4.6 SOUTH KOREA 164
10.4.6.1 Growing geriatric population with chronic kidney disease to propel market growth 164
10.4.7 REST OF ASIA PACIFIC 167
10.5 LATIN AMERICA 169
10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 169
10.5.2 BRAZIL 172
10.5.2.1 Brazil to account for largest share of Latin American market during forecast period 172
10.5.3 MEXICO 174
10.5.3.1 Increasing patient population and growing middle class population to boost market growth 174
10.5.4 REST OF LATIN AMERICA 176
10.6 MIDDLE EAST & AFRICA 178
10.6.1 GROWING DEMAND FOR CONVENIENT AND ACCESSIBLE RENAL CARE TO PROPEL GROWTH 178
10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 179
10.7 GCC COUNTRIES 182
10.7.1 HIGHER DISPOSABLE INCOME AND INCREASED GOVERNMENT HEALTHCARE EXPENDITURE TO PROPEL MARKET GROWTH 182
10.7.2 MACROECONOMIC OUTLOOK FOR GCC COUNTRIES 182
11 COMPETITIVE LANDSCAPE 185
11.1 OVERVIEW 185
11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 185
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN PERITONEAL DIALYSIS MARKET 186
11.3 REVENUE ANALYSIS, 2019–2023 187
11.4 MARKET SHARE ANALYSIS, 2023 188
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023 190
11.5.1 STARS 190
11.5.2 EMERGING LEADERS 191
11.5.3 PERVASIVE PLAYERS 191
11.5.4 PARTICIPANTS 191
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 192
11.5.5.1 Company footprint 192
11.5.5.2 Offering footprint 193
11.5.5.3 Modality footprint 194
11.5.5.4 Disease indication footprint 195
11.5.5.5 End-user footprint 196
11.5.5.6 Region footprint 197
11.6 COMPANY EVALUATION MATRIX: START-UPS/SMES, 2023 197
11.6.1 PROGRESSIVE COMPANIES 197
11.6.2 RESPONSIVE COMPANIES 198
11.6.3 DYNAMIC COMPANIES 198
11.6.4 STARTING BLOCKS 198
11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023 199
11.7 COMPANY VALUATION & FINANCIAL METRICS 200
11.8 COMPETITIVE SCENARIO 201
11.8.1 PRODUCT APPROVALS 201
11.8.2 DEALS 201
11.8.3 EXPANSIONS 202
11.9 BRAND/PRODUCT COMPARISON 203
11.10 PERITONEAL DIALYSIS MARKET: R&D EXPENDITURE 204
12 COMPANY PROFILES 205
12.1 KEY PLAYERS 205
12.1.1 FRESENIUS MEDICAL CARE AG 205
12.1.1.1 Business overview 205
12.1.1.2 Products & services offered 206
12.1.1.3 Recent developments 208
12.1.1.3.1 Deals 208
12.1.1.4 MnM view 208
12.1.1.4.1 Right to win 208
12.1.1.4.2 Strategic choices 208
12.1.1.4.3 Weaknesses & competitive threats 208
12.1.2 BAXTER INTERNATIONAL INC. 209
12.1.2.1 Business overview 209
12.1.2.2 Products & services offered 211
12.1.2.3 Recent developments 212
12.1.2.3.1 Deals 212
12.1.2.4 MnM view 212
12.1.2.4.1 Right to win 212
12.1.2.4.2 Strategic choices 212
12.1.2.4.3 Weaknesses & competitive threats 212
12.1.3 MEDTRONIC PLC 213
12.1.3.1 Business overview 213
12.1.3.2 Products & services offered 215
12.1.3.3 Recent developments 215
12.1.3.3.1 Deals 215
12.1.3.4 MnM view 216
12.1.3.4.1 Right to win 216
12.1.3.4.2 Strategic choices 216
12.1.3.4.3 Weaknesses & competitive threats 216
12.1.4 DAVITA INC. 217
12.1.4.1 Business overview 217
12.1.4.2 Products & services offered 218
12.1.4.3 Recent developments 218
12.1.4.3.1 Deals 218
12.1.4.3.2 Expansions 218
12.1.4.4 MnM view 219
12.1.4.4.1 Right to win 219
12.1.4.4.2 Strategic choices 219
12.1.4.4.3 Weaknesses & competitive threats 219
12.1.5 BECTON, DICKINSON AND COMPANY 220
12.1.5.1 Business overview 220
12.1.5.2 Products & services offered 222
12.1.5.3 Recent developments 222
12.1.5.3.1 Expansions 222
12.1.5.4 MnM view 223
12.1.5.4.1 Right to win 223
12.1.5.4.2 Strategic choices 223
12.1.5.4.3 Weaknesses & competitive threats 223
12.1.6 TERUMO CORPORATION 224
12.1.6.1 Business overview 224
12.1.6.2 Products & services offered 225
12.1.6.3 Recent developments 225
12.1.6.3.1 Product approvals 225
12.1.6.3.2 Deals 226
12.1.6.3.3 Expansions 226
12.1.7 UTAH MEDICAL PRODUCTS, INC. 227
12.1.7.1 Business overview 227
12.1.7.2 Products & services offered 229
12.1.8 DIAVERUM AB 230
12.1.8.1 Business overview 230
12.1.8.2 Products & services offered 230
12.1.9 MEDIONICS 231
12.1.9.1 Business overview 231
12.1.9.2 Products & services offered 231
12.1.10 NEWSOL TECHNOLOGIES INC. 233
12.1.10.1 Business overview 233
12.1.10.2 Products & services offered 233
12.1.11 APOLLO DIALYSIS PVT. LTD. 234
12.1.11.1 Business overview 234
12.1.11.2 Products & services offered 234
12.1.12 U.S. RENAL CARE, INC. 235
12.1.12.1 Business overview 235
12.1.12.2 Products & services offered 235
12.1.13 NORTHWEST KIDNEY CENTERS 236
12.1.13.1 Business overview 236
12.1.13.2 Products & services offered 236
12.1.13.3 Recent developments 237
12.1.13.3.1 Deals 237
12.1.13.3.2 Expansions 237
12.1.14 RELAVO 238
12.1.14.1 Business overview 238
12.1.14.2 Products & services offered 238
12.1.15 MITRA INDUSTRIES PVT. LTD. 239
12.1.15.1 Business overview 239
12.1.15.2 Products & services offered 240
12.2 OTHER PLAYERS 241
12.2.1 JMS CO., LTD. 241
12.2.2 AMECATH 241
12.2.3 POLYMEDICURE 242
12.2.4 HUAREN PHARMACEUTICAL 242
12.2.5 AWAK TECHNOLOGIES 243
12.2.6 INNOVATIVE RENAL CARE 243
12.2.7 ROMSONS 244
12.2.8 SSEM MTHEMBU MEDICAL (PTY) LTD. 244
12.2.9 RENAX BIOMEDICAL TECHNOLOGY CO., LTD. 245
12.2.10 ADVIN HEALTH CARE 245
13 APPENDIX 246
13.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 249
13.2 CUSTOMIZATION OPTIONS 251
13.3 RELATED REPORTS 251
13.4 AUTHOR DETAILS 252
LIST OF TABLES
TABLE 1 STANDARD CURRENCY CONVERSION RATES 27
TABLE 2 NUMBER OF PEOPLE AGED 65 YEARS OR OVER, BY REGION, 2022 VS. 2050 54
TABLE 3 UTILIZATION OF KIDNEY REPLACEMENT THERAPIES
(PERITONEAL DIALYSIS VS. HEMODIALYSIS) 56
TABLE 4 COST OF KIDNEY REPLACEMENT THERAPIES (2021) 56
TABLE 5 TRADE ANALYSIS OF MEDICAL DEVICE PRODUCTS 63
TABLE 6 IMPORT DATA FOR PERITONEAL DIALYSIS MACHINES, SOLUTION BAGS, CATHETERS, AND TRANSFER SETS (HS CODE 9018), BY COUNTRY,
2019–2023 (USD THOUSAND) 64
TABLE 7 EXPORT DATA FOR PERITONEAL DIALYSIS MACHINES, SOLUTION BAGS, CATHETERS AND TRANSFER SETS (HS CODE 9018), BY COUNTRY,
2019–2023 (USD THOUSAND) 64
TABLE 8 PERITONEAL DIALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
TABLE 9 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 70
TABLE 10 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 70
TABLE 11 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 71
TABLE 12 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 71
TABLE 13 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 72
TABLE 14 AVERAGE SELLING PRICE OF PERITONEAL DIALYSIS PRODUCTS AND CONSUMABLES, BY KEY PLAYER, 2023 (USD) 74
TABLE 15 PERITONEAL DIALYSIS MARKET: DETAILED LIST OF KEY CONFERENCES
& EVENTS, 2024–2025 75
TABLE 16 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS FOR PERITONEAL DIALYSIS PRODUCTS 76
TABLE 17 BUYING CRITERIA FOR PERITONEAL DIALYSIS PRODUCTS 77
TABLE 18 PERITONEAL DIALYSIS MARKET: ECOSYSTEM ANALYSIS 78
TABLE 19 CASE STUDY 1: CUSTOMIZED DIALYSIS TUBING SETS 81
TABLE 20 CASE STUDY 2: CUSTOMIZED SOFTWARE FOR AUTOMATED PERITONEAL
DIALYSIS (APD) MACHINE 81
TABLE 21 PERITONEAL DIALYSIS MARKET: UNMET NEEDS 83
TABLE 22 PERITONEAL DIALYSIS MARKET: END-USER EXPECTATIONS 83
TABLE 23 PREVALENCE DATA, BY COUNTRY, 2021–2023 (PMP) 86
TABLE 24 NUMBER OF PERITONEAL DIALYSIS PATIENTS, BY REGION, 2019–2023 87
TABLE 25 NUMBER OF PERITONEAL DIALYSIS PATIENTS, BY REGION, 2024–2029 87
TABLE 26 PROCEDURE DATA FOR PERITONEAL DIALYSIS, BY COUNTRY, 2019–2023 88
TABLE 27 PROCEDURE DATA FOR PERITONEAL DIALYSIS, BY COUNTRY, 2024–2029 89
TABLE 28 PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 91
TABLE 29 PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE, 2022–2029 (USD MILLION) 92
TABLE 30 PERITONEAL DIALYSIS PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 92
TABLE 31 AVERAGE VOLUME OF EXCHANGE, BY REGION, 2019–2023 (MILLION LITERS) 93
TABLE 32 AVERAGE VOLUME OF EXCHANGE, BY REGION, 2024–2029 (MILLION LITERS) 94
TABLE 33 PERITONEAL DIALYSIS SOLUTION BAGS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 94
TABLE 34 PERITONEAL DIALYSIS SOLUTION BAGS MARKET,
BY REGION, 2022–2029 (THOUSAND UNITS) 95
TABLE 35 PERITONEAL DIALYSIS MACHINES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 96
TABLE 36 PERITONEAL DIALYSIS MACHINES MARKET, BY REGION,
2022–2029 (THOUSAND UNITS) 97
TABLE 37 PERITONEAL DIALYSIS CATHETERS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 98
TABLE 38 PERITONEAL DIALYSIS TRANSFER SETS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 99
TABLE 39 OTHER PERITONEAL DIALYSIS PRODUCTS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 100
TABLE 40 PERITONEAL DIALYSIS SERVICES MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 101
TABLE 41 PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022–2029 (USD MILLION) 103
TABLE 42 CONTINUOUS AMBULATORY PERITONEAL DIALYSIS (CAPD) MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 104
TABLE 43 AMBULATORY PERITONEAL DIALYSIS (APD) MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 105
TABLE 44 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 107
TABLE 45 PERITONEAL DIALYSIS MARKET FOR END-STAGE RENAL DISEASE,
BY REGION, 2022–2029 (USD MILLION) 108
TABLE 46 PERITONEAL DIALYSIS MARKET FOR ACUTE KIDNEY INJURY,
BY REGION, 2022–2029 (USD MILLION) 109
TABLE 47 PERITONEAL DIALYSIS MARKET FOR OTHER DISEASES,
BY COUNTRY, 2022–2029 (USD MILLION) 110
TABLE 48 PERITONEAL DIALYSIS MARKET, BY END USER, 2022–2029 (USD MILLION) 112
TABLE 49 PERITONEAL DIALYSIS MARKET FOR HOME CARE SETTINGS,
BY COUNTRY, 2022–2029 (USD MILLION) 113
TABLE 50 PERITONEAL DIALYSIS MARKET FOR HOSPITALS & INDEPENDENT DIALYSIS CENTERS, BY COUNTRY, 2022–2029 (USD MILLION) 115
TABLE 51 PERITONEAL DIALYSIS MARKET FOR OTHER END USERS,
BY COUNTRY, 2022–2029 (USD MILLION) 116
TABLE 52 PERITONEAL DIALYSIS PREVALENCE DATA, BY COUNTRY, 2019–2023 118
TABLE 53 PERITONEAL DIALYSIS PREVALENCE DATA, BY COUNTRY, 2024–2029 119
TABLE 54 PERITONEAL DIALYSIS PROCEDURE DATA, BY REGION,
2019–2023 (MILLION PROCEDURES) 119
TABLE 55 PERITONEAL DIALYSIS PROCEDURE DATA, BY REGION,
2024–2029 (MILLION PROCEDURES) 120
TABLE 56 PERITONEAL DIALYSIS MARKET, BY REGION, 2022–2029 (USD MILLION) 120
TABLE 57 NORTH AMERICA: PERITONEAL DIALYSIS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 123
TABLE 58 NORTH AMERICA: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 123
TABLE 59 NORTH AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 123
TABLE 60 NORTH AMERICA: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 124
TABLE 61 NORTH AMERICA: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 124
TABLE 62 NORTH AMERICA: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 125
TABLE 63 US: MACROECONOMIC INDICATORS 126
TABLE 64 US: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 126
TABLE 65 US: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 126
TABLE 66 US: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022–2029 (USD MILLION) 127
TABLE 67 US: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 127
TABLE 68 US: PERITONEAL DIALYSIS MARKET, BY END USER, 2022–2029 (USD MILLION) 127
TABLE 69 CANADA: MACROECONOMIC INDICATORS 128
TABLE 70 CANADA: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2022–2029 (USD MILLION) 129
TABLE 71 CANADA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 129
TABLE 72 CANADA: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2022–2029 (USD MILLION) 129
TABLE 73 CANADA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 130
TABLE 74 CANADA: PERITONEAL DIALYSIS MARKET, BY END USER,
2022–2029 (USD MILLION) 130
TABLE 75 EUROPE: PERITONEAL DIALYSIS MARKET, BY COUNTRY,
2022–2029 (USD MILLION) 131
TABLE 76 EUROPE: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2022–2029 (USD MILLION) 132
TABLE 77 EUROPE: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 132
TABLE 78 EUROPE: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2022–2029 (USD MILLION) 132
TABLE 79 EUROPE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 133
TABLE 80 EUROPE: PERITONEAL DIALYSIS MARKET, BY END USER,
2022–2029 (USD MILLION) 133
TABLE 81 GERMANY: MACROECONOMIC INDICATORS 134
TABLE 82 GERMANY: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2022–2029 (USD MILLION) 134
TABLE 83 GERMANY: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 134
TABLE 84 GERMANY: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2022–2029 (USD MILLION) 135
TABLE 85 GERMANY: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 135
TABLE 86 GERMANY: PERITONEAL DIALYSIS MARKET, BY END USER,
2022–2029 (USD MILLION) 135
TABLE 87 UK: MACROECONOMIC INDICATORS 136
TABLE 88 UK: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 136
TABLE 89 UK: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 137
TABLE 90 UK: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022–2029 (USD MILLION) 137
TABLE 91 UK: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 137
TABLE 92 UK: PERITONEAL DIALYSIS MARKET, BY END USER, 2022–2029 (USD MILLION) 138
TABLE 93 FRANCE: MACROECONOMIC INDICATORS 139
TABLE 94 FRANCE: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2022–2029 (USD MILLION) 139
TABLE 95 FRANCE: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 139
TABLE 96 FRANCE: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2022–2029 (USD MILLION) 140
TABLE 97 FRANCE: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 140
TABLE 98 FRANCE: PERITONEAL DIALYSIS MARKET, BY END USER,
2022–2029 (USD MILLION) 140
TABLE 99 ITALY: MACROECONOMIC INDICATORS 141
TABLE 100 ITALY: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 141
TABLE 101 ITALY: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 142
TABLE 102 ITALY: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022–2029 (USD MILLION) 142
TABLE 103 ITALY: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 142
TABLE 104 ITALY: PERITONEAL DIALYSIS MARKET, BY END USER, 2022–2029 (USD MILLION) 143
TABLE 105 SPAIN: MACROECONOMIC INDICATORS 143
TABLE 106 SPAIN: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 144
TABLE 107 SPAIN: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 144
TABLE 108 SPAIN: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022–2029 (USD MILLION) 144
TABLE 109 SPAIN: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 145
TABLE 110 SPAIN: PERITONEAL DIALYSIS MARKET, BY END USER, 2022–2029 (USD MILLION) 145
TABLE 111 REST OF EUROPE: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2022–2029 (USD MILLION) 146
TABLE 112 REST OF EUROPE: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 146
TABLE 113 REST OF EUROPE: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 147
TABLE 114 REST OF EUROPE: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 147
TABLE 115 REST OF EUROPE: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 148
TABLE 116 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 151
TABLE 117 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 151
TABLE 118 ASIA PACIFIC: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 152
TABLE 119 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 152
TABLE 120 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 153
TABLE 121 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 153
TABLE 122 JAPAN: MACROECONOMIC INDICATORS 154
TABLE 123 JAPAN: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 154
TABLE 124 JAPAN: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 155
TABLE 125 JAPAN: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022–2029 (USD MILLION) 155
TABLE 126 JAPAN: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 156
TABLE 127 JAPAN: PERITONEAL DIALYSIS MARKET, BY END USER, 2022–2029 (USD MILLION) 156
TABLE 128 CHINA: MACROECONOMIC INDICATORS 157
TABLE 129 CHINA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 158
TABLE 130 CHINA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 158
TABLE 131 CHINA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022–2029 (USD MILLION) 158
TABLE 132 CHINA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 159
TABLE 133 CHINA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022–2029 (USD MILLION) 159
TABLE 134 INDIA: MACROECONOMIC INDICATORS 160
TABLE 135 INDIA: PERITONEAL DIALYSIS MARKET, BY OFFERING, 2022–2029 (USD MILLION) 160
TABLE 136 INDIA: PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2022–2029 (USD MILLION) 160
TABLE 137 INDIA: PERITONEAL DIALYSIS MARKET, BY MODALITY, 2022–2029 (USD MILLION) 161
TABLE 138 INDIA: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 161
TABLE 139 INDIA: PERITONEAL DIALYSIS MARKET, BY END USER, 2022–2029 (USD MILLION) 161
TABLE 140 AUSTRALIA: MACROECONOMIC INDICATORS 162
TABLE 141 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2022–2029 (USD MILLION) 162
TABLE 142 AUSTRALIA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 163
TABLE 143 AUSTRALIA: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2022–2029 (USD MILLION) 163
TABLE 144 AUSTRALIA: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 164
TABLE 145 AUSTRALIA: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 164
TABLE 146 SOUTH KOREA: MACROECONOMIC INDICATORS 165
TABLE 147 SOUTH KOREA: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 165
TABLE 148 SOUTH KOREA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 165
TABLE 149 SOUTH KOREA: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 166
TABLE 150 SOUTH KOREA: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 166
TABLE 151 SOUTH KOREA: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 166
TABLE 152 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 167
TABLE 153 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 167
TABLE 154 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 168
TABLE 155 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 168
TABLE 156 REST OF ASIA PACIFIC: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 168
TABLE 157 LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY COUNTRY, 2022–2029 (USD MILLION) 169
TABLE 158 LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 170
TABLE 159 LATIN AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 170
TABLE 160 LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 171
TABLE 161 LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 171
TABLE 162 LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 171
TABLE 163 BRAZIL: MACROECONOMIC INDICATORS 172
TABLE 164 BRAZIL: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2022–2029 (USD MILLION) 172
TABLE 165 BRAZIL: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 173
TABLE 166 BRAZIL: PERITONEAL DIALYSIS MARKET, BY MODALITY,
2022–2029 (USD MILLION) 173
TABLE 167 BRAZIL: PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2022–2029 (USD MILLION) 173
TABLE 168 BRAZIL: PERITONEAL DIALYSIS MARKET, BY END USER,
2022–2029 (USD MILLION) 174
TABLE 169 MEXICO: MACROECONOMIC INDICATORS 174
TABLE 170 MEXICO: PERITONEAL DIALYSIS MARKET, BY OFFERING,
2022–2029 (USD MILLION) 175
TABLE 171 MEXICO: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 175
TABLE 172 MEXICO: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 175
TABLE 173 MEXICO: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 176
TABLE 174 MEXICO: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 176
TABLE 175 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 177
TABLE 176 REST OF LATIN AMERICA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 177
TABLE 177 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 177
TABLE 178 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 178
TABLE 179 REST OF LATIN AMERICA: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 178
TABLE 180 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 180
TABLE 181 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 180
TABLE 182 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 181
TABLE 183 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 181
TABLE 184 MIDDLE EAST & AFRICA: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 181
TABLE 185 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET,
BY OFFERING, 2022–2029 (USD MILLION) 183
TABLE 186 GCC COUNTRIES: PERITONEAL DIALYSIS PRODUCTS MARKET,
BY TYPE, 2022–2029 (USD MILLION) 183
TABLE 187 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET,
BY MODALITY, 2022–2029 (USD MILLION) 183
TABLE 188 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET,
BY DISEASE INDICATION, 2022–2029 (USD MILLION) 184
TABLE 189 GCC COUNTRIES: PERITONEAL DIALYSIS MARKET,
BY END USER, 2022–2029 (USD MILLION) 184
TABLE 190 PERITONEAL DIALYSIS MARKET: DEGREE OF COMPETITION 189
TABLE 191 PERITONEAL DIALYSIS MARKET: OFFERING FOOTPRINT 193
TABLE 192 PERITONEAL DIALYSIS MARKET: MODALITY FOOTPRINT 194
TABLE 193 PERITONEAL DIALYSIS MARKET: DISEASE INDICATION FOOTPRINT 195
TABLE 194 PERITONEAL DIALYSIS MARKET: END-USER FOOTPRINT 196
TABLE 195 PERITONEAL DIALYSIS MARKET: REGION FOOTPRINT 197
TABLE 196 PERITONEAL DIALYSIS MARKET: DETAILED LIST OF KEY START-UP/SME PLAYERS 199
TABLE 197 PERITONEAL DIALYSIS MARKET: COMPETITIVE BENCHMARKING OF
KEY START-UP/SME PLAYERS REGION FOOTPRINT 199
TABLE 198 PERITONEAL DIALYSIS MARKET: PRODUCT APPROVALS
(JANUARY 2021- SEPTEMBER 2024) 201
TABLE 199 PERITONEAL DIALYSIS MARKET: DEALS, JANUARY 2020–SEPTEMBER 2024 201
TABLE 200 PERITONEAL DIALYSIS MARKET: EXPANSIONS, JANUARY 2020–SEPTEMBER 2024 202
TABLE 201 FRESENIUS MEDICAL CARE AG: COMPANY OVERVIEW 205
TABLE 202 FRESENIUS MEDICAL CARE AG: PRODUCTS & SERVICES OFFERED 206
TABLE 203 FRESENIUS MEDICAL CARE AG: DEALS, JANUARY 2021–SEPTEMBER 2024 208
TABLE 204 BAXTER INTERNATIONAL INC.: COMPANY OVERVIEW 209
TABLE 205 BAXTER INTERNATIONAL INC.: PRODUCTS & SERVICES OFFERED 211
TABLE 206 BAXTER INTERNATIONAL INC.: DEALS, JANUARY 2021–SEPTEMBER 2024 212
TABLE 207 MEDTRONIC PLC: COMPANY OVERVIEW 213
TABLE 208 MEDTRONIC PLC: PRODUCTS & SERVICES OFFERED 215
TABLE 209 MEDTRONIC PLC: DEALS, JANUARY 2021–SEPTEMBER 2024 215
TABLE 210 DAVITA INC.: COMPANY OVERVIEW 217
TABLE 211 DAVITA INC.: PRODUCTS & SERVICES OFFERED 218
TABLE 212 DAVITA INC.: DEALS, JANUARY 2021–SEPTEMBER 2024 218
TABLE 213 DAVITA INC.: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 218
TABLE 214 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 220
TABLE 215 BECTON, DICKINSON AND COMPANY: PRODUCTS & SERVICES OFFERED 222
TABLE 216 BECTON, DICKINSON AND COMPANY: EXPANSIONS,
JANUARY 2021–SEPTEMBER 2024 222
TABLE 217 TERUMO CORPORATION: COMPANY OVERVIEW 224
TABLE 218 TERUMO CORPORATION: PRODUCTS & SERVICES OFFERED 225
TABLE 219 TERUMO CORPORATION: PRODUCT APPROVALS,
JANUARY 2021–SEPTEMBER 2024 225
TABLE 220 TERUMO CORPORATION: DEALS, JANUARY 2021–SEPTEMBER 2024 226
TABLE 221 TERUMO CORPORATION: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 226
TABLE 222 UTAH MEDICAL PRODUCTS, INC.: BUSINESS OVERVIEW 227
TABLE 223 UTAH MEDICAL PRODUCTS, INC.: PRODUCTS & SERVICES OFFERED 229
TABLE 224 DIAVERUM AB: COMPANY OVERVIEW 230
TABLE 225 DIAVERUM AB: PRODUCTS & SERVICES OFFERED 230
TABLE 226 MEDIONICS: BUSINESS OVERVIEW 231
TABLE 227 MEDIONICS: PRODUCTS & SERVICES OFFERED 231
TABLE 228 NEWSOL TECHNOLOGIES INC.: COMPANY OVERVIEW 233
TABLE 229 NEWSOL TECHNOLOGIES INC.: PRODUCTS & SERVICES OFFERED 233
TABLE 230 APOLLO DIALYSIS PVT. LTD.: BUSINESS OVERVIEW 234
TABLE 231 APOLLO DIALYSIS PVT. LTD.: PRODUCTS & SERVICES OFFERED 234
TABLE 232 U.S. RENAL CARE, INC.: BUSINESS OVERVIEW 235
TABLE 233 U.S. RENAL CARE, INC.: PRODUCTS & SERVICES OFFERED 235
TABLE 234 NORTHWEST KIDNEY CENTERS: COMPANY OVERVIEW 236
TABLE 235 NORTHWEST KIDNEY CENTERS: PRODUCTS & SERVICES OFFERED 236
TABLE 236 NORTHWEST KIDNEY CENTERS: DEALS, JANUARY 2021–SEPTEMBER 2024 237
TABLE 237 NORTHWEST KIDNEY CENTERS: EXPANSIONS, JANUARY 2021–SEPTEMBER 2024 237
TABLE 238 RELAVO: COMPANY OVERVIEW 238
TABLE 239 RELAVO: PRODUCTS & SERVICES OFFERED 238
TABLE 240 MITRA INDUSTRIES PVT. LTD.: BUSINESS OVERVIEW 239
TABLE 241 MITRA INDUSTRIES PVT. LTD.: PRODUCTS & SERVICES OFFERED 240
LIST OF FIGURES
FIGURE 1 PERITONEAL DIALYSIS MARKET: SEGMENTS COVERED 26
FIGURE 2 RESEARCH DESIGN: PERITONEAL DIALYSIS MARKET 29
FIGURE 3 INDICATIVE LIST OF SECONDARY SOURCES 31
FIGURE 4 LIST OF KEY PRIMARY SOURCES 32
FIGURE 5 KEY INDUSTRY INSIGHTS 33
FIGURE 6 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS 33
FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,
AND REGION 34
FIGURE 8 MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS 35
FIGURE 9 REVENUE SHARE ANALYSIS ILLUSTRATION 35
FIGURE 10 SUPPLY-SIDE MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS MARKET (2023) 36
FIGURE 11 ESTIMATION OF PERITONEAL DIALYSIS PROCEDURES, BY COUNTRY/REGION 37
FIGURE 12 MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS MARKET, BY PRODUCT UTILIZATION METHODOLOGY 38
FIGURE 13 MARKET SIZE ESTIMATION: PERITONEAL DIALYSIS SERVICES MARKET, BY REVENUE MAPPING METHODOLOGY 38
FIGURE 14 PERITONEAL DIALYSIS: AVERAGE VOLUME EXCHANGE ESTIMATION MODEL 39
FIGURE 15 CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES (2024–2029) 40
FIGURE 16 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 40
FIGURE 17 DATA TRIANGULATION METHODOLOGY 41
FIGURE 18 PERITONEAL DIALYSIS MARKET, BY OFFERING, 2024 VS. 2029 (USD MILLION) 43
FIGURE 19 PERITONEAL DIALYSIS PRODUCTS MARKET, BY TYPE,
2024 VS. 2029 (USD MILLION) 44
FIGURE 20 PERITONEAL DIALYSIS MARKET, BY MODALITY, 2024 VS. 2029 (USD MILLION) 44
FIGURE 21 PERITONEAL DIALYSIS MARKET, BY DISEASE INDICATION,
2024 VS. 2029 (USD MILLION) 45
FIGURE 22 PERITONEAL DIALYSIS MARKET, BY END USER, 2024 VS. 2029 (USD MILLION) 46
FIGURE 23 GEOGRAPHIC SNAPSHOT: PERITONEAL DIALYSIS MARKET 47
FIGURE 24 INCREASING PREVALENCE OF ESRD TO DRIVE MARKET GROWTH 48
FIGURE 25 JAPAN ACCOUNTED FOR LARGEST SHARE OF ASIA PACIFIC MARKET IN 2023 49
FIGURE 26 INDIA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 50
FIGURE 27 NORTH AMERICA TO CONTINUE TO DOMINATE PERITONEAL DIALYSIS MARKET DURING FORECAST PERIOD 51
FIGURE 28 DEVELOPING ECONOMIES TO REGISTER HIGHER GROWTH DURING
FORECAST PERIOD 51
FIGURE 29 PERITONEAL DIALYSIS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES,
AND CHALLENGES 52
FIGURE 30 CANADA: NUMBER OF END-STAGE RENAL DISEASE PATIENTS,
BY AGE GROUP (2022) 53
FIGURE 31 US: REPORTED CAUSES OF END-STAGE RENAL DISEASES, 2023 55
FIGURE 32 INCIDENCE OF TREATED END-STAGE RENAL DISEASE, 2021 57
FIGURE 33 SHORTAGES OF NEPHROLOGISTS IN LOW-INCOME AND LOWER-MIDDLE-INCOME COUNTRIES (LLMICS) 59
FIGURE 34 PERITONEAL DIALYSIS MARKET: SUPPLY CHAIN ANALYSIS 62
FIGURE 35 PERITONEAL DIALYSIS MARKET: VALUE CHAIN ANALYSIS 63
FIGURE 36 PERITONEAL DIALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 65
FIGURE 37 PATENT PUBLICATION TRENDS (2014–2024) 72
FIGURE 38 TOP APPLICANTS AND OWNERS (COMPANIES/INSTITUTIONS) FOR PERITONEAL DIALYSIS PATENTS (JANUARY 2014–SEPTEMBER 2024) 73
FIGURE 39 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR PERITONEAL
DIALYSIS PRODUCTS 76
FIGURE 40 KEY BUYING CRITERIA FOR PERITONEAL DIALYSIS PRODUCTS 77
FIGURE 41 HEMODIALYSIS AND PERITONEAL DIALYSIS MARKET OVERVIEW 79
FIGURE 42 CONTINUOUS RENAL REPLACEMENT THERAPY MARKET OVERVIEW 80
FIGURE 43 KEY FEATURES OF GENERATIVE AI IN PERITONEAL DIALYSIS MARKET 82
FIGURE 44 PERITONEAL DIALYSIS MARKET: TRENDS/DISRUPTIONS AFFECTING
CUSTOMERS’ BUSINESSES 84
FIGURE 45 NUMBER OF DEALS & FUNDING ACTIVITY IN PERITONEAL DIALYSIS MARKET, 2019–2023 (USD MILLION) 84
FIGURE 46 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 85
FIGURE 47 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 (USD MILLION) 85
FIGURE 48 NORTH AMERICA: PERITONEAL DIALYSIS MARKET SNAPSHOT 122
FIGURE 49 ASIA PACIFIC: PERITONEAL DIALYSIS MARKET SNAPSHOT 150
FIGURE 50 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PRODUCT & SERVICE COMPANIES 186
FIGURE 51 REVENUE ANALYSIS OF TOP THREE PLAYERS IN PERITONEAL
DIALYSIS MARKET (2019–2023) 187
FIGURE 52 MARKET SHARE ANALYSIS OF KEY PLAYERS IN PERITONEAL
DIALYSIS MARKET (2023) 188
FIGURE 53 PERITONEAL DIALYSIS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2023 191
FIGURE 54 PERITONEAL DIALYSIS MARKET: COMPANY FOOTPRINT 192
FIGURE 55 PERITONEAL DIALYSIS MARKET: COMPANY EVALUATION MATRIX
(START-UPS/SMES), 2023 198
FIGURE 56 EV/EBITDA OF KEY VENDORS 200
FIGURE 57 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK
BETA OF KEY VENDORS 200
FIGURE 58 BRAND/PRODUCT COMPARATIVE ANALYSIS 203
FIGURE 59 R&D EXPENDITURE OF KEY PLAYERS (2022 VS. 2023) 204
FIGURE 60 FRESENIUS MEDICAL CARE AG: COMPANY SNAPSHOT (2023) 206
FIGURE 61 BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT (2023) 210
FIGURE 62 MEDTRONIC PLC: COMPANY SNAPSHOT (2023) 214
FIGURE 63 DAVITA INC.: COMPANY SNAPSHOT (2023) 217
FIGURE 64 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2023) 221
FIGURE 65 TERUMO CORPORATION: COMPANY SNAPSHOT (2023) 224
FIGURE 66 UTAH MEDICAL PRODUCTS, INC.: COMPANY SNAPSHOT (2023) 228
MarketsandMarkets（マーケッツアンドマーケッツ）は世界中の企業に高い評価を得ており、著名メディアでの引用頻度も高い、インドの最大手級の市場調査会社です。広範な市場を対象にした市場調査レポートを出版しています。
※MarketsandMarketsの調査レポートはほぼ全タイトルご注文後、最短3時間～12時間以内（営業日基準）にご納品可能です。
ライセンス別価格表
調査会社の事情により予告なしに変更されることがございます。最新の状況およびその他のパターンについてはお問い合わせください。
ライセンスタイプ1
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD4,950 | USD6,650 | USD8,150 | USD10,000 |
ライセンスタイプ2
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD7,150 | USD8,500 | USD9,650 | USD11,000 |
ライセンスタイプ3
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD8,150 | お問合せください | お問合せください | お問合せください |
ライセンスタイプ4
| シングルユーザ | マルチユーザ | コーポレート | エンタープライズサイト |
| USD9,000 | USD10,500 | USD12,000 | USD13,500 |
ミニレポート ※定性調査にフォーカスした調査レポートです。詳細はお問合せください。
| シングルユーザ | コーポレート |
| USD 2,650 | USD 4,250 |
ご購入に関するご案内
価格・納期について
- 価格
- ウェブサイトに記載の外貨（定価）を見積日のTTSレートで換算後消費税を加えた金額が弊社からの請求金額になります。見積金額はレート変動に関係なく見積書発行日より2週間有効です。手数料（ハンドリングチャージ）無料。
- ライセンス
- シングルユーザライセンス
- 1名のみレポートファイルのご利用が可能です。
- マルチユーザライセンス
- 同一企業内（関連会社除く）5名までレポートファイルのご利用が可能です。
- コーポレートライセンス
- 同一企業および100％持株会社間・人数無制限でレポートファイルのご利用が可能です。
- エンタープライズサイトライセンス
- 特別ライセンスです。適用範囲についてはお問合せください。
- シングルユーザライセンス
- 納品形態
- Eメール
- 納期
- 最短3時間以内にご納品可能です。通常ご注文後24時間以内（営業日基準）
ご注文方法
- レポートページ内のお問い合わせフォームより見積もりをご請求ください。確認次第見積書と発注書をお送りいたします。既に弊社の見積書をお持ちの場合にはEメールまたはFAXでご注文ください。
その他
- 商品の性質上、ご注文後のキャンセル/返品/交換はできません。ご了承ください。
株式会社SEMABIZはMarketsandMarketsの日本に拠点をおく販売代理店として、MarketsandMarketsのレポートを販売しております。サンプルページのご依頼、見積り、レポートに関するご質問など購入前のご相談はいつでもお気軽にご連絡ください。
最新調査レポート
- 自動車用アラミド繊維市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- ポリヒドロキシアルカノエート (PHA) 市場規模、シェア、動向、2030年までの世界予測 2025-12-15
- 複合輸送市場規模、シェア、動向、2032年までの世界予測 2025-12-12
- 有機酸市場規模、シェア、動向、2030年までの世界予測 2025-12-11
- ハイブリッドボンディング市場規模、シェア、動向、2032年までの世界予測 2025-12-11